The goal of this clinical trial is to learn about the impact of a point-of-care test for gonorrhea and chlamydia in people without symptoms who are seeking sexually transmitted infection testing. The main questions it aims to answer are:
Does the point of care test reduce the time to antibiotic treatment? Does the point of care test increase the number of people who have completed treatment by day 7?
Researchers will compare the point-of-care test to a standard laboratory-based test for gonorrhea and chlamydia.
Participants will be asked to provide a urine sample or vaginal swab for testing. They will also complete surveys about their experiences with the testing.
At least 18 years of age
Willing and able to provide informed consent
Asymptomatic at the urogenital site
Being screened for urogenital C. trachomatis and/or N. gonorrhoeae as part of routine clinical care
Indication for antimicrobial therapy for C. trachomatis or N. gonorrhoeae at the time of the visit, regardless of test results
Massachusetts General Hospital
Lead sponsor
Roche Diagnostic Ltd.
Collaborator